Treatment of acute hepatitis C genotypes 1 and 4 with 8 weeks of grazoprevir plus elbasvir (DAHHS2): an open-label, multicentre, single-arm, phase 3b trial. [electronic resource]
Producer: 20200527Description: 269-277 p. digitalISSN:- 2468-1253
- Acute Disease
- Administration, Oral
- Adult
- Amides
- Antiviral Agents -- administration & dosage
- Belgium -- epidemiology
- Benzofurans -- administration & dosage
- Carbamates
- Cyclopropanes
- Drug Therapy, Combination -- methods
- Female
- Genotype
- Hepacivirus -- drug effects
- Hepatitis C -- drug therapy
- Humans
- Imidazoles -- administration & dosage
- Incidence
- Male
- Middle Aged
- Netherlands -- epidemiology
- Quinoxalines -- administration & dosage
- Sexually Transmitted Diseases -- epidemiology
- Sulfonamides
- Sustained Virologic Response
- Time Factors
- Treatment Failure
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.